| 177 | Humans (MeSH) |
| 154 | Pandemics (MeSH) |
| 102 | Betacoronavirus (MeSH) |
| 90 | Pneumonia, Viral (epidemiology) |
| 90 | Coronavirus Infections (epidemiology) |
| 51 | Pneumonia, Viral (complications) |
| 51 | Coronavirus Infections (complications) |
| 47 | Male (MeSH) |
| 47 | Comorbidity (MeSH) |
| 46 | Female (MeSH) |
| 43 | Risk Factors (MeSH) |
| 43 | Aged (MeSH) |
| 39 | Middle Aged (MeSH) |
| 35 | Pneumonia, Viral (therapy) |
| 35 | Coronavirus Infections (therapy) |
| 35 | Cardiovascular Diseases (epidemiology) |
| 33 | Coronavirus Infections (diagnosis) |
| 31 | Pneumonia, Viral (diagnosis) |
| 27 | Pneumonia, Viral (virology) |
| 27 | Coronavirus Infections (virology) |
| 25 | Coronavirus Infections (drug therapy) |
| 25 | Adult (MeSH) |
| 23 | Prognosis (MeSH) |
| 22 | Pandemics (prevention & control) |
| 22 | Cardiovascular Diseases (complications) |
| 20 | Pneumonia, Viral (mortality) |
| 20 | Coronavirus Infections (mortality) |
| 19 | Risk Assessment (MeSH) |
| 19 | Pneumonia, Viral (drug therapy) |
| 18 | Retrospective Studies (MeSH) |
| 18 | Pneumonia, Viral (prevention & control) |
| 18 | Pneumonia, Viral (physiopathology) |
| 18 | Coronavirus Infections (prevention & control) |
| 18 | Coronavirus Infections (physiopathology) |
| 17 | Severity of Illness Index (MeSH) |
| 17 | China (epidemiology) |
| 17 | Cardiovascular Diseases (therapy) |
| 16 | Peptidyl-Dipeptidase A (metabolism) |
| 16 | Betacoronavirus (isolation & purification) |
| 16 | Aged, 80 and over (MeSH) |
| 15 | Pneumonia, Viral (MeSH) |
| 14 | Coronavirus Infections (MeSH) |
| 14 | Cardiovascular Diseases (virology) |
| 13 | Cardiovascular Diseases (drug therapy) |
| 13 | Cardiovascular Diseases (diagnosis) |
| 13 | Betacoronavirus (physiology) |
| 13 | Betacoronavirus (pathogenicity) |
| 12 | Prevalence (MeSH) |
| 12 | Pneumonia, Viral (pathology) |
| 12 | Coronavirus Infections (pathology) |
| 11 | Young Adult (MeSH) |
| 11 | Diabetes Mellitus (epidemiology) |
| 11 | Age Factors (MeSH) |
| 10 | Treatment Outcome (MeSH) |
| 10 | Renin-Angiotensin System (drug effects) |
| 10 | Incidence (MeSH) |
| 10 | Global Health (MeSH) |
| 10 | Adolescent (MeSH) |
| 9 | Survival Analysis (MeSH) |
| 9 | Renin-Angiotensin System (physiology) |
| 9 | Pneumonia, Viral (immunology) |
| 9 | Coronavirus Infections (immunology) |
| 9 | Animals (MeSH) |
| 9 | Angiotensin-Converting Enzyme Inhibitors (therapeutic use) |
| 8 | United States (epidemiology) |
| 8 | Pneumonia, Viral (metabolism) |
| 8 | Coronavirus Infections (transmission) |
| 8 | Coronavirus Infections (metabolism) |
| 8 | Coronavirus (MeSH) |
| 8 | Child (MeSH) |
| 8 | Biomarkers (blood) |
| 8 | Angiotensin-Converting Enzyme Inhibitors (adverse effects) |
| 7 | Practice Guidelines as Topic (MeSH) |
| 7 | Pneumonia, Viral (transmission) |
| 7 | Intensive Care Units (MeSH) |
| 7 | Hypertension (epidemiology) |
| 7 | Hospitalization (statistics & numerical data) |
| 7 | Cardiovascular Diseases (etiology) |
| 7 | Cardiovascular Diseases (MeSH) |
| 7 | Antiviral Agents (therapeutic use) |
| 7 | Angiotensin Receptor Antagonists (adverse effects) |
| 6 | Sex Factors (MeSH) |
| 6 | Hypertension (drug therapy) |
| 6 | Hospitalization (MeSH) |
| 6 | Critical Illness (MeSH) |
| 6 | Betacoronavirus (drug effects) |
| 6 | Angiotensin Receptor Antagonists (therapeutic use) |
| 5 | Tomography, X-Ray Computed (MeSH) |
| 5 | Pneumonia, Viral (etiology) |
| 5 | Hospital Mortality (MeSH) |
| 5 | Consensus (MeSH) |
| 5 | China (MeSH) |
| 5 | Cause of Death (MeSH) |
| 5 | Cardiovascular Diseases (mortality) |
| 5 | Cardiology (MeSH) |
| 4 | United Kingdom (epidemiology) |
| 4 | Societies, Medical (MeSH) |
| 4 | Sedentary Behavior (MeSH) |
| 4 | Renin-Angiotensin System (MeSH) |
| 4 | Receptors, Virus (metabolism) |
| 4 | Randomized Controlled Trials as Topic (MeSH) |
| 4 | Personal Protective Equipment (MeSH) |
| 4 | Peptidyl-Dipeptidase A (physiology) |
| 4 | Peptidyl-Dipeptidase A (genetics) |
| 4 | Hypertension (complications) |
| 4 | Fever (virology) |
| 4 | Europe (MeSH) |
| 4 | Diabetes Mellitus (drug therapy) |
| 4 | Critical Care (MeSH) |
| 4 | Cough (virology) |
| 4 | Coronavirus Infections (etiology) |
| 4 | Clinical Laboratory Techniques (MeSH) |
| 4 | Chronic Disease (MeSH) |
| 4 | Child, Preschool (MeSH) |
| 4 | Cardiovascular Diseases (prevention & control) |
| 4 | Cardiovascular Diseases (pathology) |
| 4 | Angiotensin-Converting Enzyme Inhibitors (pharmacology) |
| 3 | Tomography, X-Ray Computed (methods) |
| 3 | Time Factors (MeSH) |
| 3 | Spain (epidemiology) |
| 3 | Socioeconomic Factors (MeSH) |
| 3 | Signal Transduction (MeSH) |
| 3 | Renal Dialysis (MeSH) |
| 3 | Receptors, Virus (genetics) |
| 3 | Radiography, Thoracic (methods) |
| 3 | Quarantine (MeSH) |
| 3 | Pulmonary Disease, Chronic Obstructive (epidemiology) |
| 3 | Prospective Studies (MeSH) |
| 3 | Pregnancy (MeSH) |
| 3 | Pneumonia, Viral (diagnostic imaging) |
| 3 | Pneumonia, Viral (blood) |
| 3 | Pandemics (statistics & numerical data) |
| 3 | Neoplasms (epidemiology) |
| 3 | Neoplasms (diagnosis) |
| 3 | Neoplasms (complications) |
| 3 | Mice (MeSH) |
| 3 | Logistic Models (MeSH) |
| 3 | Infant (MeSH) |
| 3 | Hypoglycemic Agents (adverse effects) |
| 3 | Hydroxychloroquine (therapeutic use) |
| 3 | Hydroxychloroquine (adverse effects) |
| 3 | Heart Failure (therapy) |
| 3 | Heart Failure (epidemiology) |
| 3 | Heart Diseases (virology) |
| 3 | Heart Diseases (etiology) |
| 3 | Drug Combinations (MeSH) |
| 3 | Disease Progression (MeSH) |
| 3 | Disease Outbreaks (MeSH) |
| 3 | Disease Management (MeSH) |
| 3 | Diabetes Mellitus (therapy) |
| 3 | Diabetes Mellitus (diagnosis) |
| 3 | Cost of Illness (MeSH) |
| 3 | Coronavirus Infections (blood) |
| 3 | Clinical Laboratory Techniques (methods) |
| 3 | Cardiovascular Diseases (physiopathology) |
| 3 | Cardiovascular Diseases (metabolism) |
| 3 | Cardiovascular Diseases (chemically induced) |
| 3 | Blood Glucose (metabolism) |
| 3 | Betacoronavirus (genetics) |
| 3 | Antihypertensive Agents (adverse effects) |
| 3 | Angiotensin Receptor Antagonists (pharmacology) |
| 3 | Alanine (analogs & derivatives) |
| 3 | Adenosine Monophosphate (analogs & derivatives) |
| 2 | Troponin (blood) |
| 2 | Triage (MeSH) |
| 2 | Thromboembolism (MeSH) |
| 2 | Telemedicine (organization & administration) |
| 2 | Telemedicine (MeSH) |
| 2 | Spike Glycoprotein, Coronavirus (metabolism) |
| 2 | Severe Acute Respiratory Syndrome (epidemiology) |
| 2 | Serine Endopeptidases (metabolism) |
| 2 | Ritonavir (therapeutic use) |
| 2 | Risk Assessment (methods) |
| 2 | Respiratory Distress Syndrome, Adult (etiology) |
| 2 | Respiration, Artificial (statistics & numerical data) |
| 2 | Respiration, Artificial (MeSH) |
| 2 | Registries (MeSH) |
| 2 | Receptors, Virus (physiology) |
| 2 | Quarantine (psychology) |
| 2 | Quarantine (methods) |
| 2 | Public Health (MeSH) |
| 2 | Proportional Hazards Models (MeSH) |
| 2 | Primary Prevention (MeSH) |
| 2 | Pneumonia, Viral (ethnology) |
| 2 | Pneumonia, Viral (enzymology) |
| 2 | Pneumonia, Viral (chemically induced) |
| 2 | Percutaneous Coronary Intervention (MeSH) |
| 2 | Odds Ratio (MeSH) |
| 2 | Obesity (epidemiology) |
| 2 | New York City (epidemiology) |
| 2 | Neoplasms (drug therapy) |
| 2 | Myocardium (pathology) |
| 2 | Myocarditis (virology) |
| 2 | Myocarditis (complications) |
| 2 | Myocardial Infarction (therapy) |
| 2 | Myocardial Infarction (etiology) |
| 2 | Mortality (MeSH) |
| 2 | Models, Statistical (MeSH) |
| 2 | Mineralocorticoid Receptor Antagonists (pharmacology) |
| 2 | Lung Diseases (epidemiology) |
| 2 | Lung Diseases (complications) |
| 2 | Lopinavir (therapeutic use) |
| 2 | Kidney Failure, Chronic (therapy) |
| 2 | Italy (epidemiology) |
| 2 | Inflammation (MeSH) |
| 2 | Infection Control (organization & administration) |
| 2 | Infection Control (MeSH) |
| 2 | Infant, Newborn (MeSH) |
| 2 | Immunosuppressive Agents (therapeutic use) |
| 2 | Hypoglycemic Agents (therapeutic use) |
| 2 | Hypertension (mortality) |
| 2 | Hypertension (metabolism) |
| 2 | Host Microbial Interactions (MeSH) |
| 2 | Heart Failure (virology) |
| 2 | Heart Failure (etiology) |
| 2 | Heart Diseases (therapy) |
| 2 | Heart Diseases (complications) |
| 2 | Heart (virology) |
| 2 | Health Personnel (MeSH) |
| 2 | Follow-Up Studies (MeSH) |
| 2 | Fatigue (virology) |
| 2 | Extracorporeal Membrane Oxygenation (MeSH) |
| 2 | Enzyme Inhibitors (adverse effects) |
| 2 | Disinfection (MeSH) |
| 2 | Disease Susceptibility (MeSH) |
| 2 | Disease Outbreaks (statistics & numerical data) |
| 2 | Diet (methods) |
| 2 | Diet (adverse effects) |
| 2 | Diabetes Mellitus, Type 2 (epidemiology) |
| 2 | Diabetes Mellitus, Type 2 (drug therapy) |
| 2 | Diabetes Mellitus (virology) |
| 2 | Diabetes Mellitus (mortality) |
| 2 | Diabetes Complications (virology) |
| 2 | Diabetes Complications (therapy) |
| 2 | Diabetes Complications (MeSH) |
| 2 | Delivery of Health Care (MeSH) |
| 2 | Databases, Factual (MeSH) |
| 2 | Coronavirus Infections (ethnology) |
| 2 | Coronavirus Infections (enzymology) |
| 2 | Coronavirus Infections (diagnostic imaging) |
| 2 | Coronavirus Infections (chemically induced) |
| 2 | Communicable Disease Control (MeSH) |
| 2 | Combined Modality Therapy (MeSH) |
| 2 | Cohort Studies (MeSH) |
| 2 | Clinical Protocols (MeSH) |
| 2 | Cardiovascular Diseases (enzymology) |
| 2 | Cardiovascular Diseases (diagnostic imaging) |
| 2 | Cardiology (standards) |
| 2 | Cardiologists (MeSH) |
| 2 | Body Mass Index (MeSH) |
| 2 | Blood Glucose (drug effects) |
| 2 | Betacoronavirus (metabolism) |
| 2 | Betacoronavirus (immunology) |
| 2 | Azithromycin (therapeutic use) |
| 2 | Azithromycin (adverse effects) |
| 2 | Asthma (epidemiology) |
| 2 | Arrhythmias, Cardiac (virology) |
| 2 | Arrhythmias, Cardiac (complications) |
| 2 | Antimalarials (therapeutic use) |
| 2 | Antihypertensive Agents (therapeutic use) |
| 2 | Antihypertensive Agents (administration & dosage) |
| 2 | Anti-Bacterial Agents (therapeutic use) |
| 2 | Angiotensin II Type 1 Receptor Blockers (pharmacology) |
| 2 | Alanine (therapeutic use) |
| 2 | Aging (MeSH) |
| 2 | Adrenal Cortex Hormones (therapeutic use) |
| 2 | Adenosine Monophosphate (therapeutic use) |
| 1 | Washington (MeSH) |
| 1 | Vulnerable Populations (MeSH) |
| 1 | Vitamin D (therapeutic use) |
| 1 | Visual Field Tests (MeSH) |
| 1 | Virus Internalization (MeSH) |
| 1 | Virus Attachment (MeSH) |
| 1 | Viral Proteins (metabolism) |
| 1 | Viral Proteins (genetics) |
| 1 | Viral Proteins (chemistry) |
| 1 | Viral Nonstructural Proteins (genetics) |
| 1 | Vagus Nerve Stimulation (instrumentation) |
| 1 | Urban Population (statistics & numerical data) |
| 1 | Up-Regulation (MeSH) |
| 1 | United Kingdom (MeSH) |
| 1 | Turkey (MeSH) |
| 1 | Tuberculosis (immunology) |
| 1 | Troponin T (blood) |
| 1 | Troponin I (blood) |
| 1 | Travel (MeSH) |
| 1 | Tertiary Care Centers (statistics & numerical data) |
| 1 | Telemedicine (methods) |
| 1 | Telemedicine (instrumentation) |
| 1 | Takotsubo Cardiomyopathy (virology) |
| 1 | Takotsubo Cardiomyopathy (etiology) |
| 1 | Symptom Assessment (statistics & numerical data) |
| 1 | Symptom Assessment (methods) |
| 1 | Symptom Assessment (MeSH) |
| 1 | Sweden (epidemiology) |
| 1 | Survival Rate (trends) |
| 1 | Survival Rate (MeSH) |
| 1 | Stroke (therapy) |
| 1 | Stroke (epidemiology) |
| 1 | Stroke (blood) |
| 1 | Statistics, Nonparametric (MeSH) |
| 1 | State Medicine (MeSH) |
| 1 | Spike Glycoprotein, Coronavirus (genetics) |
| 1 | Specimen Handling (MeSH) |
| 1 | Somatostatin (therapeutic use) |
| 1 | Somatostatin (analogs & derivatives) |
| 1 | Social Support (MeSH) |
| 1 | Social Isolation (psychology) |
| 1 | Social Isolation (MeSH) |
| 1 | Social Distance (MeSH) |
| 1 | Single-Cell Analysis (MeSH) |
| 1 | Signal Transduction (drug effects) |
| 1 | Shock, Septic (MeSH) |
| 1 | Shock, Cardiogenic (therapy) |
| 1 | Shock, Cardiogenic (etiology) |
| 1 | Shock (therapy) |
| 1 | Severe Acute Respiratory Syndrome (virology) |
| 1 | Severe Acute Respiratory Syndrome (immunology) |
| 1 | Severe Acute Respiratory Syndrome (diagnosis) |
| 1 | Sequence Alignment (MeSH) |
| 1 | Self Efficacy (MeSH) |
| 1 | Secondary Prevention (trends) |
| 1 | Secondary Prevention (methods) |
| 1 | SARS Virus (MeSH) |
| 1 | Rural Population (statistics & numerical data) |
| 1 | Risk Reduction Behavior (MeSH) |
| 1 | Risk Management (MeSH) |
| 1 | Risk (MeSH) |
| 1 | Reverse Transcriptase Polymerase Chain Reaction (MeSH) |
| 1 | Respiratory Insufficiency (virology) |
| 1 | Respiratory Insufficiency (complications) |
| 1 | Respiratory Distress Syndrome, Adult (virology) |
| 1 | Respiratory Distress Syndrome, Adult (therapy) |
| 1 | Respiratory Distress Syndrome, Adult (immunology) |
| 1 | Respiratory Distress Syndrome, Adult (epidemiology) |
| 1 | Respiratory Distress Syndrome, Adult (MeSH) |
| 1 | Respiration Disorders (etiology) |
| 1 | Residence Characteristics (statistics & numerical data) |
| 1 | Research Design (MeSH) |
| 1 | Republic of Korea (epidemiology) |
| 1 | Renin (antagonists & inhibitors) |
| 1 | Renal Insufficiency, Chronic (therapy) |
| 1 | Renal Insufficiency, Chronic (epidemiology) |
| 1 | Renal Dialysis (statistics & numerical data) |
| 1 | Renal Dialysis (methods) |
| 1 | Remote Consultation (methods) |
| 1 | Regeneration (MeSH) |
| 1 | Reference Values (MeSH) |
| 1 | Recurrence (MeSH) |
| 1 | Recombinant Proteins (therapeutic use) |
| 1 | Recombinant Proteins (pharmacology) |
| 1 | Receptors, Virus (antagonists & inhibitors) |
| 1 | Receptors, Notch (metabolism) |
| 1 | Receptors, Notch (antagonists & inhibitors) |
| 1 | Receptor, Angiotensin, Type 1 (metabolism) |
| 1 | Receptor, Angiotensin, Type 1 (genetics) |
| 1 | Rats, Inbred Lew (MeSH) |
| 1 | Rats (MeSH) |
| 1 | Rare Diseases (complications) |
| 1 | Ramipril (adverse effects) |
| 1 | Radiotherapy (MeSH) |
| 1 | Radiography, Thoracic (MeSH) |
| 1 | ROC Curve (MeSH) |
| 1 | RNA, Viral (chemistry) |
| 1 | RNA, Viral (analysis) |
| 1 | RNA Splicing (MeSH) |
| 1 | RNA Splice Sites (MeSH) |
| 1 | Quarantine (organization & administration) |
| 1 | Pulmonary Disease, Chronic Obstructive (physiopathology) |
| 1 | Pulmonary Disease, Chronic Obstructive (complications) |
| 1 | Public Policy (MeSH) |
| 1 | PubMed (MeSH) |
| 1 | Propensity Score (MeSH) |
| 1 | Professional Practice (MeSH) |
| 1 | Procedures and Techniques Utilization (MeSH) |
| 1 | Primary Prevention (trends) |
| 1 | Primary Prevention (methods) |
| 1 | Prenatal Diagnosis (methods) |
| 1 | Prenatal Care (trends) |
| 1 | Prenatal Care (organization & administration) |
| 1 | Prenatal Care (methods) |
| 1 | Pregnancy, High-Risk (MeSH) |
| 1 | Pregnancy Complications, Infectious (virology) |
| 1 | Pregnancy Complications, Infectious (epidemiology) |
| 1 | Pregnancy Complications (prevention & control) |
| 1 | Pregnancy Complications (diagnosis) |
| 1 | Precision Medicine (MeSH) |
| 1 | Poverty (statistics & numerical data) |
| 1 | Population Surveillance (methods) |
| 1 | Population Surveillance (MeSH) |
| 1 | Poland (MeSH) |
| 1 | Pneumonia, Viral (psychology) |
| 1 | Pneumonia, Viral (genetics) |
| 1 | Pneumonia, Viral (economics) |
| 1 | Pneumonia, Viral (diet therapy) |
| 1 | Platelet Aggregation Inhibitors (administration & dosage) |
| 1 | Pituitary Neoplasms (therapy) |
| 1 | Pituitary Neoplasms (diagnosis) |
| 1 | Pituitary Apoplexy (therapy) |
| 1 | Pituitary Apoplexy (diagnosis) |
| 1 | Physical Fitness (MeSH) |
| 1 | Phenotype (MeSH) |
| 1 | Peripheral Arterial Disease (pathology) |
| 1 | Perioperative Care (MeSH) |
| 1 | Pericytes (virology) |
| 1 | Pericytes (enzymology) |
| 1 | Peptidyl-Dipeptidase A (therapeutic use) |
| 1 | Peptidyl-Dipeptidase A (pharmacology) |
| 1 | Peptidyl-Dipeptidase A (drug effects) |
| 1 | Peptidyl-Dipeptidase A (deficiency) |
| 1 | Peptidyl-Dipeptidase A (blood) |
| 1 | Peptides, Cyclic (therapeutic use) |
| 1 | Peptide Fragments (therapeutic use) |
| 1 | Peptide Fragments (blood) |
| 1 | Patient Transfer (MeSH) |
| 1 | Patient Education as Topic (MeSH) |
| 1 | Patient Discharge (statistics & numerical data) |
| 1 | Patient Discharge (standards) |
| 1 | Patient Care Management (methods) |
| 1 | Patient Care (statistics & numerical data) |
| 1 | Patient Care (standards) |
| 1 | Patient Admission (statistics & numerical data) |
| 1 | Patient Acuity (MeSH) |
| 1 | Pandemics (economics) |
| 1 | Oxygen Inhalation Therapy (MeSH) |
| 1 | Oxidative Phosphorylation (MeSH) |
| 1 | Overweight (epidemiology) |
| 1 | Outpatient Clinics, Hospital (organization & administration) |
| 1 | Oral Hygiene (MeSH) |
| 1 | Octreotide (therapeutic use) |
| 1 | Observational Studies as Topic (MeSH) |
| 1 | Obesity (virology) |
| 1 | Obesity (physiopathology) |
| 1 | Obesity (pathology) |
| 1 | Obesity (immunology) |
| 1 | Obesity (complications) |
| 1 | Nucleic Acid Conformation (MeSH) |
| 1 | Non-Randomized Controlled Trials as Topic (MeSH) |
| 1 | Nomograms (MeSH) |
| 1 | New Orleans (epidemiology) |
| 1 | Neurosurgical Procedures (MeSH) |
| 1 | Nephrology (standards) |
| 1 | Neovascularization, Physiologic (MeSH) |
| 1 | Neoplasms (therapy) |
| 1 | Neoplasms (pathology) |
| 1 | Neoplasms (mortality) |
| 1 | Natriuretic Peptide, Brain (blood) |
| 1 | Nasal Mucosa (immunology) |
| 1 | Nasal Mucosa (cytology) |
| 1 | Myocytes, Cardiac (virology) |
| 1 | Myocytes, Cardiac (pathology) |
| 1 | Myocardium (enzymology) |
| 1 | Myocarditis (therapy) |
| 1 | Myocarditis (pathology) |
| 1 | Myocarditis (etiology) |
| 1 | Myocardial Ischemia (therapy) |
| 1 | Myocardial Infarction (virology) |
| 1 | Myocardial Infarction (epidemiology) |
| 1 | Myocardial Infarction (complications) |
| 1 | Mycobacterium tuberculosis (MeSH) |
| 1 | Myalgia (virology) |
| 1 | Myalgia (epidemiology) |
| 1 | Mutation (MeSH) |
| 1 | Muscle, Skeletal (pathology) |
| 1 | Muscle, Skeletal (metabolism) |
| 1 | Muscle Development (MeSH) |
| 1 | Muscle Cells (metabolism) |
| 1 | Multiple Organ Failure (mortality) |
| 1 | Multiple Organ Failure (etiology) |
| 1 | Multiple Organ Failure (diagnosis) |
| 1 | Multiple Chronic Conditions (epidemiology) |
| 1 | Mucocutaneous Lymph Node Syndrome (diagnosis) |
| 1 | Molecular Targeted Therapy (MeSH) |
| 1 | Minority Groups (MeSH) |
| 1 | Mineralocorticoid Receptor Antagonists (therapeutic use) |
| 1 | Mineralocorticoid Receptor Antagonists (adverse effects) |
| 1 | Microtubule-Associated Proteins (metabolism) |
| 1 | MicroRNAs (metabolism) |
| 1 | MicroRNAs (genetics) |
| 1 | MicroRNAs (chemistry) |
| 1 | Mice, Knockout (MeSH) |
| 1 | Mice, Inbred C57BL (MeSH) |
| 1 | Mexico (epidemiology) |
| 1 | Mexico (MeSH) |
| 1 | Methylprednisolone (therapeutic use) |
| 1 | Metabolic Syndrome (virology) |
| 1 | Metabolic Syndrome (physiopathology) |
| 1 | Metabolic Syndrome (etiology) |
| 1 | Metabolic Diseases (prevention & control) |
| 1 | Metabolic Diseases (immunology) |
| 1 | Metabolic Diseases (diet therapy) |
| 1 | Mental Health (MeSH) |
| 1 | Melatonin (therapeutic use) |
| 1 | Medicine, Chinese Traditional (MeSH) |
| 1 | Medication Therapy Management (MeSH) |
| 1 | Medical Oncology (statistics & numerical data) |
| 1 | Macaca mulatta (MeSH) |
| 1 | Lymphopenia (etiology) |
| 1 | Lymphocyte Count (MeSH) |
| 1 | Lymphocyte Activation (immunology) |
